MCID: NSL008
MIFTS: 38

Nasal Cavity Cancer

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Nasal Cavity Cancer

MalaCards integrated aliases for Nasal Cavity Cancer:

Name: Nasal Cavity Cancer 12 14
Nasal Cavity Carcinoma 12 14 69
Neoplasm of Nasal Cavity 12 69
Nasal Cavity Neoplasm 12 14
Malignant Neoplasm of Nasal Cavities 12
Malignant Tumor of the Nasal Cavity 12
Malignant Neoplasm of Nasal Cavity 69
Carcinoma of Nasal Cavity 12
Tumor of the Nasal Cavity 12
Cancer of Nasal Cavity 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10811 DOID:4931 DOID:9310
ICD10 32 C30.0
ICD9CM 34 160.0

Summaries for Nasal Cavity Cancer

Disease Ontology : 12 A nasal cavity cancer that_has material basis in epithelial cells.

MalaCards based summary : Nasal Cavity Cancer, also known as nasal cavity carcinoma, is related to nasal cavity adenocarcinoma and nasal cavity squamous cell carcinoma, and has symptoms including rhinorrhea and pain. An important gene associated with Nasal Cavity Cancer is CXCL11 (C-X-C Motif Chemokine Ligand 11), and among its related pathways/superpathways is Cytoskeleton remodeling Neurofilaments. The drugs Bupropion and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and prostate, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Nasal Cavity Cancer

Diseases in the Nasal Cavity Cancer family:

Nasal Cavity Carcinoma in Situ

Diseases related to Nasal Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
# Related Disease Score Top Affiliating Genes
1 nasal cavity adenocarcinoma 31.2 CXCL11 KRT7 PDYN
2 nasal cavity squamous cell carcinoma 29.8 ANKRD11 CXCL11 KRT7 KRT8 SLC25A19
3 nasal cavity carcinoma in situ 12.2
4 nasal cavity cancer, childhood 12.2
5 olfactory neuroblastoma 10.2
6 middle ear carcinoma 10.2
7 hemangiopericytoma, malignant 10.2
8 proliferating trichilemmal cyst 10.1 KRT7 KRT8
9 endolymphatic sac tumor 10.1 KRT7 KRT8
10 cutaneous adenocystic carcinoma 10.1 KRT7 KRT8
11 hidrocystoma 10.1 KRT7 KRT8
12 prostate squamous cell carcinoma 10.1 KRT7 KRT8
13 apocrine sweat gland neoplasm 10.1 KRT7 KRT8
14 brooke-spiegler syndrome 10.1 KRT7 KRT8
15 pleomorphic carcinoma 10.1 KRT7 KRT8
16 mucinous tubular and spindle renal cell carcinoma 10.1 KRT7 KRT8
17 fibrolamellar carcinoma 10.1 KRT7 KRT8
18 atypical choroid plexus papilloma 10.1 KRT7 KRT8
19 lymphoepithelioma-like carcinoma 10.1 KRT7 KRT8
20 immune system organ benign neoplasm 10.1 KRT7 KRT8
21 thymus lipoma 10.1 KRT7 KRT8
22 breast secretory carcinoma 10.1 KRT7 KRT8
23 basaloid squamous cell carcinoma 10.1 KRT7 KRT8
24 gastric tubular adenocarcinoma 10.0 KRT7 KRT8
25 mammary paget's disease 10.0 KRT7 KRT8
26 intraneural perineurioma 10.0 KRT7 KRT8
27 nephrogenic adenofibroma 10.0 KRT7 KRT8
28 secretory meningioma 10.0 KRT7 KRT8
29 sweat gland cancer 10.0 KRT7 KRT8
30 epithelioid sarcoma 10.0 KRT7 KRT8
31 primary cutaneous amyloidosis 10.0 KRT7 KRT8
32 adenosquamous carcinoma 10.0 KRT7 KRT8
33 oncocytoma 10.0 KRT7 KRT8
34 chromophobe renal cell carcinoma 9.9 KRT7 KRT8
35 craniopharyngioma 9.9 KRT7 KRT8
36 merkel cell carcinoma 9.9 KRT7 KRT8
37 sarcoma, synovial 9.9 KRT7 KRT8
38 transitional cell carcinoma 9.8 KRT7 KRT8
39 sinusitis 9.8
40 papilloma 9.7 KRT7 KRT8
41 cholangiocarcinoma 9.6 KRT7 KRT8

Graphical network of the top 20 diseases related to Nasal Cavity Cancer:



Diseases related to Nasal Cavity Cancer

Symptoms & Phenotypes for Nasal Cavity Cancer

UMLS symptoms related to Nasal Cavity Cancer:


rhinorrhea, pain

GenomeRNAi Phenotypes related to Nasal Cavity Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.23 KRT8
2 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.23 KRT7 KRT8
3 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.23 KRT7 KRT8
4 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.23 KRT8
5 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.23 KRT7 KRT8

Drugs & Therapeutics for Nasal Cavity Cancer

Drugs for Nasal Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupropion Approved Phase 4,Phase 2 34911-55-2, 34841-39-9 444
2
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
3
Nicotine Approved Phase 4 54-11-5 89594 942
4 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
5 Liver Extracts Phase 4,Phase 2
6 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
7 Antidepressive Agents Phase 4,Phase 2
8 Antidepressive Agents, Second-Generation Phase 4,Phase 2
9 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
10 Dopamine Agents Phase 4,Phase 2
11 Dopamine Uptake Inhibitors Phase 4,Phase 2
12 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
13 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
14 Psychotropic Drugs Phase 4,Phase 2
15 Autonomic Agents Phase 4,Phase 2,Phase 3
16 Central Nervous System Stimulants Phase 4
17 Cholinergic Agents Phase 4,Phase 2,Phase 3
18 Nicotinic Agonists Phase 4
19
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 2767 441203 84093
20
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
21
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
22
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
23
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2 114977-28-5 148124 9877265
24 Antimetabolites Phase 3,Phase 1,Phase 2
25 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
26 Antimitotic Agents Phase 3,Phase 1,Phase 2
27 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
28 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
29 Fluorides Phase 3,Phase 1,Phase 2
30 Lemon Balm Nutraceutical Phase 3
31
Amifostine Approved, Investigational Phase 1, Phase 2 20537-88-6 2141
32
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
33
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
34
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
35
Indinavir Approved Phase 2 150378-17-9 5362440
36
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
37
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
38
Zinc Approved, Investigational Phase 2 7440-66-6 32051 23994
39
Zinc oxide Approved Phase 2 1314-13-2
40
nivolumab Approved Phase 2 946414-94-4
41 Raspberry Approved, Nutraceutical Phase 1, Phase 2
42 Albumin-Bound Paclitaxel Phase 1, Phase 2
43 Antineoplastic Agents, Phytogenic Phase 1, Phase 2
44 Protective Agents Phase 1, Phase 2
45 Radiation-Protective Agents Phase 1, Phase 2
46 Anti-Infective Agents Phase 1, Phase 2
47 Antiviral Agents Phase 1, Phase 2
48 Analgesics Phase 2
49 Analgesics, Non-Narcotic Phase 2
50 Anti-Inflammatory Agents Phase 2

Interventional clinical trials:

(show all 43)

# Name Status NCT ID Phase Drugs
1 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
2 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Unknown status NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
4 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
5 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
6 Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer Active, not recruiting NCT01141231 Phase 3
7 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
8 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
9 Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
10 Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
11 Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Unknown status NCT00052611 Phase 2 celecoxib
12 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
13 Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer Completed NCT00462735 Phase 2 cetuximab;hydroxyurea;fluorouracil
14 Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00002951 Phase 2 fluorouracil;hydroxyurea
15 Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract Completed NCT00524017 Phase 2
16 Bupropion in Helping Adults Stop Smoking Completed NCT00534001 Phase 2 bupropion hydrochloride
17 Zinc Supplements in Lowering Cadmium Levels in Smokers Completed NCT00376987 Phase 2
18 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Completed NCT00833261 Phase 2 cetuximab;cisplatin
19 Trial of Induction Therapy With Docetaxel, Cisplatin and Fluorouracil in Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma and/or Poorly Differentiated Carcinoma of the Nasal Cavity and/or Paranasal Sinuses Recruiting NCT00707473 Phase 2 Docetaxel;5-Fluorouracil;Cisplatin
20 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
21 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
22 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Active, not recruiting NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
23 Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer Terminated NCT00003489 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
24 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer Unknown status NCT00004097 Phase 1 fluorouracil;gemcitabine hydrochloride;paclitaxel
25 Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors Unknown status NCT00978081 Phase 1 aminolevulinic acid hydrochloride
26 Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer Completed NCT00036790 Phase 1 doxorubicin hydrochloride;motexafin gadolinium
27 L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors Completed NCT00003430 Phase 1 L-778,123
28 EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma Terminated NCT00004261 Phase 1 EF5
29 ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer Withdrawn NCT00006106 Phase 1 cisplatin;fluorouracil;ONYX-015
30 Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer Unknown status NCT01254591
31 Photon/Proton Radiation Therapy for Cancers of the Nasal Cavity and/or Paranasal Sinuses Completed NCT00797498
32 Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer Completed NCT00019201
33 Acceptability of Less Harmful Alternatives to Cigarettes Completed NCT00957424 nicotine replacement therapy
34 Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking Completed NCT00790569 nicotine;varenicline
35 Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic Completed NCT00533884
36 Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy Completed NCT00310115
37 Computer-Assisted Scheduling of Nicotine Inhaler Use in Participants Who Plan to Stop Smoking Completed NCT00021138 nicotine
38 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
39 Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers Recruiting NCT00900419
40 Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use Active, not recruiting NCT00799669
41 Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure Active, not recruiting NCT00530049
42 Electroacupuncture in Treating Chronic Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer Terminated NCT00623129
43 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors Withdrawn NCT00499291 paclitaxel albumin-stabilized nanoparticle formulation

Search NIH Clinical Center for Nasal Cavity Cancer

Genetic Tests for Nasal Cavity Cancer

Anatomical Context for Nasal Cavity Cancer

MalaCards organs/tissues related to Nasal Cavity Cancer:

38
Lung, Breast, Prostate, Brain, Liver

Publications for Nasal Cavity Cancer

Articles related to Nasal Cavity Cancer:

# Title Authors Year
1
(P092) definitive chemoradiotherapy or radiotherapy for unresectable, very locally advanced, or medically inoperable paranasal sinus and nasal cavity cancer. ( 25930909 )
2015
2
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQAr): Health Professional Version ( 26389272 )
2002
3
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQAr): Health Professional Version ( 26425762 )
2002
4
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQAr): Patient Version ( 27559600 )
2002
5
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQAr): Patient Version ( 27195380 )
2002
6
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQAr): Patient Version ( 26389439 )
2002
7
Nasal obstruction portending nasal cavity cancer. ( 2599810 )
1989
8
Paranasal sinuses and nasal cavity cancer: different radiotherapeutic options, results and late damages. ( 3810867 )
1986

Variations for Nasal Cavity Cancer

Expression for Nasal Cavity Cancer

Search GEO for disease gene expression data for Nasal Cavity Cancer.

Pathways for Nasal Cavity Cancer

Pathways related to Nasal Cavity Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.66 KRT7 KRT8

GO Terms for Nasal Cavity Cancer

Cellular components related to Nasal Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratin filament GO:0045095 8.62 KRT7 KRT8

Biological processes related to Nasal Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cornification GO:0070268 8.62 KRT7 KRT8

Sources for Nasal Cavity Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....